基于流行病学因素和遗传变异确定Barrett食管与食管腺癌风险
该研究利用国际Barrett食管与食管腺癌联盟及英国两项研究的3288例Barrett食管、2511例食管腺癌和2177例对照数据,构建基于23个遗传变异的多基因风险评分,并与人口学、生活方式及胃食管反流症状联合建模。多基因风险评分最高四分位者Barrett食管风险为最低四分位的2.22倍、食管腺癌为2.46倍,但加入评分后AUC提升有限,作者认为绝对改善幅度不足以支持临床使用。
要点
- 多基因风险评分最高四分位者Barrett食管风险是最低四分位的2.22倍(95%CI 1.89-2.60)。
- 多基因风险评分最高四分位者食管腺癌风险是最低四分位的2.46倍(95%CI 2.07-2.92)。
- 仅用人口学或生活方式因素或胃食管反流症状的模型AUC为0.637至0.667。
核心结论
- 研究开发了基于遗传、临床和人口学/生活方式因素的风险预测模型,多基因风险评分可提高对Barrett食管和食管腺癌的区分度与净重分类,但绝对改善幅度不足以支持其临床使用。
研究设计与样本
- 研究采用国际Barrett食管与食管腺癌联盟及英国Barrett食管基因研究、胃与食管癌研究的汇总数据,纳入3288例Barrett食管患者、2511例食管腺癌患者和2177例无这两种疾病的对照。
- 研究收集了23个与Barrett食管或食管腺癌风险相关的遗传变异,以全基因组关联研究提取的效应估计值(比值比)的自然对数加权风险等位基因计数,构建多基因风险评分。
- 研究还收集了年龄、性别、吸烟、体重指数、非甾体抗炎药使用等人口学和生活因素以及胃食管反流病症状,并比较不同组合模型的识别准确性(AUC分析)。
主要发现
- 基于遗传因素(多基因风险评分)最高四分位风险者Barrett食管风险是最低四分位者的2.22倍(比值比2.22,95%CI 1.89-2.60)。
- 基于遗传因素(多基因风险评分)最高四分位风险者食管腺癌风险是最低四分位者的2.46倍(比值比2.46,95%CI 2.07-2.92)。
- 仅基于人口学或生活方式因素或胃食管反流症状的模型识别Barrett食管或食管腺癌的AUC值为0.637至0.667。
- 将人口学或生活方式因素与胃食管反流症状数据联合,识别Barrett食管的AUC为0.793,识别食管腺癌的AUC为0.745。
- 在这些数据中加入多基因风险评分仅使AUC轻微增加:Barrett食管增至0.799,食管腺癌增至0.754;在基于非遗传因素的模型中加入多基因风险评分,Barrett食管的净重分类改善为3.0%,食管腺癌为5.6%。
关键数值与推荐
- 多基因风险评分最高四分位 vs 最低四分位:Barrett食管比值比2.22(95%CI 1.89-2.60),食管腺癌比值比2.46(95%CI 2.07-2.92)。
- 仅人口学或生活方式因素或胃食管反流症状模型:AUC 0.637至0.667。
- 人口学或生活方式因素联合胃食管反流症状:Barrett食管AUC 0.793,食管腺癌AUC 0.745。
- 联合多基因风险评分后:Barrett食管AUC 0.799,食管腺癌AUC 0.754。
- 加入多基因风险评分后净重分类改善:Barrett食管3.0%,食管腺癌5.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出多基因风险评分带来的绝对改善幅度不足以支持其临床使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We developed comprehensive models to determine risk of Barrett's esophagus (BE) or esophageal adenocarcinoma (EAC) based on genetic and non-genetic factors. METHODS: We used pooled data from 3288 patients with BE, 2511 patients with EAC, and 2177 individuals without either (controls) from participants in the international Barrett's and EAC consortium as well as the United Kingdom's BE gene study and stomach and esophageal cancer study. We collected data on 23 genetic variants associated with risk for BE or EAC, and constructed a polygenic risk score (PRS) for cases and controls by summing the risk allele counts for the variants weighted by their natural log-transformed effect estimates (odds ratios) extracted from genome-wide association studies. We also collected data on demographic and lifestyle factors (age, sex, smoking, body mass index, use of nonsteroidal anti-inflammatory drugs) and symptoms of gastroesophageal reflux disease (GERD). Risk models with various combinations of non-genetic factors and the PRS were compared for their accuracy in identifying patients with BE or EAC using the area under the receiver operating characteristic curve (AUC) analysis. RESULTS: Individuals in the highest quartile of risk, based on genetic factors (PRS), had a 2-fold higher risk of BE (odds ratio, 2.22; 95% confidence interval, 1.89-2.60) or EAC (odds ratio, 2.46; 95% confidence interval, 2.07-2.92) than individual in the lowest quartile of risk based on PRS. Risk models developed based on only demographic or lifestyle factors or GERD symptoms identified patients with BE or EAC with AUC values ranging from 0.637 to 0.667. Combining data on demographic or lifestyle factors with data on GERD symptoms identified patients with BE with an AUC of 0.793 and patients with EAC with an AUC of 0.745. Including PRSs with these data only minimally increased the AUC values for BE (to 0.799) and EAC (to 0.754). Including the PRSs in the model developed based on non-genetic factors resulted in a net reclassification improvement for BE of 3.0% and for EAC of 5.6%. CONCLUSIONS: We used data from 3 large databases of patients from studies of BE or EAC to develop a risk prediction model based on genetic, clinical, and demographic/lifestyle factors. We identified a PRS that increases discrimination and net reclassification of individuals with vs without BE and EAC. However, the absolute magnitude of improvement is not sufficient to justify its clinical use.
引用
- Dong J, Buas MF, Gharahkhani P, et al. Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. Gastroenterology. 2017. PMID: 29247777. doi:10.1053/j.gastro.2017.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。